Clinical Trials Directory

Trials / Completed

CompletedNCT02963389

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim After Single Administration in Pediatric Solid Tumor/Lymphoma Patients

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
27 (actual)
Sponsor
Dong-A ST Co., Ltd. · Industry
Sex
All
Age
6 Years – 19 Years
Healthy volunteers
Not accepted

Summary

This is an open-label, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of Tripegfilgrastim in pediatric solid tumor/lymphoma patients

Conditions

Interventions

TypeNameDescription
DRUGTripegfilgrastim

Timeline

Start date
2016-10-04
Primary completion
2018-11-01
Completion
2018-11-01
First posted
2016-11-15
Last updated
2019-01-15

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02963389. Inclusion in this directory is not an endorsement.

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid T (NCT02963389) · Clinical Trials Directory